Clinical Trials Browser

Phase 3 × INDUSTRY × mobocertinib × Clear all

NCT04129502 2025-04-22

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Phase 3 Active not recruiting

Carcinoma, Non-Small-Cell Lung